Wei Bi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wei Bi has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Zhaohao Zeng
Jinan University First Affiliated Hospital
5 shared publicationsLihong Zhu
School of Medicine, Jinan University
3 shared publicationsLu Wang
Jinan University First Affiliated Hospital
3 shared publicationsRixin Luo
Department of Neurology The First Affiliated Hospital, Jinan University Guangzhou People's Republic of China
3 shared publicationsAo Pan
The First Affiliated Hospital of Jinan University
2 shared publicationsJiawei Zhang
Department of Pathophysiology Key Laboratory of State Administration of Traditional Chinese Medicine of the People's Republic of China, School of Medicine, Jinan University Guangzhou People's Republic of China
2 shared publications
Latest Publications
- 7 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1356
GPR75 mediates hyperuricemia-induced endothelial inflammatory injury via a HOTAIR/miR-141-3p regulatory network
- 7 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1356
GPR75 mediates hyperuricemia-induced endothelial inflammatory injury via a HOTAIR/miR-141-3p regulatory network
- Open Access
- 20 April 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (2)
Development and validation of a prediction model for severe disturbance of consciousness in patients with non-traumatic intracranial hemorrhage using albumin-corrected anion gap: A retrospective cohort study
Objective: The aims of this study were to develop and validate a prediction model for severe disturbance of consciousness (SDOC) occurring within 30 days of intensive care unit (ICU) admission in patients with non-traumatic intracranial hemorrhage (NTICH), and to compare and validate the predictive value of anion gap (AG), serum albumin, and albumin-corrected anion gap (ACAG) for SDOC in this population. Methods: This study is a retrospective cohort study. It included a total of 873 patients with NTICH from the Medical Information Mart for Intensive Care (MIMIC-IV) database. These patients were randomly allocated in a 7:3 ratio to a training cohort (n = 611) and a validation cohort (n = 262). Variables selected from the Least Absolute Shrinkage and Selection Operator (LASSO) regression were subsequently entered into a multivariable logistic regression analysis, with those demonstrating a P-value< 0.05 incorporated into the final model to develop a dynamic nomogram. The discriminative ability of the model was evaluated by receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC). Model performance was assessed using calibration curves and the Hosmer-Lemeshow goodness-of-fit test (HL test). Furthermore, decision curve analysis (DCA) was employed to evaluate the net clinical benefit of the model. Results: We developed a 14-variable prediction model for the occurrence of SDOC within 30 days of NTICH patients’ ICU admission. The prediction model demonstrated satisfactory discriminative ability in the validation cohort, with an AUC of 0.870. Notably, ACAG showed superior predictive performance compared to AG and serum albumin alone. The constructed nomogram exhibited good calibration performance. DCA further confirmed the clinical utility of this predictive model. Conclusions: This study developed a prediction model for estimating the risk of SDOC within 30 days of admission in patients with NTICH. Furthermore, ACAG demonstrated significant importance in patients who developed SDOC.
- 20 April 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (2)
Open AccessDevelopment and validation of a prediction model for severe disturbance of consciousness in patients with non-traumatic intracranial hemorrhage using albumin-corrected anion gap: A retrospective cohort study
Objective: The aims of this study were to develop and validate a prediction model for severe disturbance of consciousness (SDOC) occurring within 30 days of intensive care unit (ICU) admission in patients with non-traumatic intracranial hemorrhage (NTICH), and to compare and validate the predictive value of anion gap (AG), serum albumin, and albumin-corrected anion gap (ACAG) for SDOC in this population. Methods: This study is a retrospective cohort study. It included a total of 873 patients with NTICH from the Medical Information Mart for Intensive Care (MIMIC-IV) database. These patients were randomly allocated in a 7:3 ratio to a training cohort (n = 611) and a validation cohort (n = 262). Variables selected from the Least Absolute Shrinkage and Selection Operator (LASSO) regression were subsequently entered into a multivariable logistic regression analysis, with those demonstrating a P-value< 0.05 incorporated into the final model to develop a dynamic nomogram. The discriminative ability of the model was evaluated by receiver operating characteristic (ROC) curves and calculating the area under the curve (AUC). Model performance was assessed using calibration curves and the Hosmer-Lemeshow goodness-of-fit test (HL test). Furthermore, decision curve analysis (DCA) was employed to evaluate the net clinical benefit of the model. Results: We developed a 14-variable prediction model for the occurrence of SDOC within 30 days of NTICH patients’ ICU admission. The prediction model demonstrated satisfactory discriminative ability in the validation cohort, with an AUC of 0.870. Notably, ACAG showed superior predictive performance compared to AG and serum albumin alone. The constructed nomogram exhibited good calibration performance. DCA further confirmed the clinical utility of this predictive model. Conclusions: This study developed a prediction model for estimating the risk of SDOC within 30 days of admission in patients with NTICH. Furthermore, ACAG demonstrated significant importance in patients who developed SDOC.
- 20 December 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 21
Efficacy of lecanemab in early-onset Alzheimer’s disease with a novel PSEN1 (p.Met233Thr) mutation: a case report
- 20 December 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 21
Efficacy of lecanemab in early-onset Alzheimer’s disease with a novel PSEN1 (p.Met233Thr) mutation: a case report
- Open Access
- 12 June 2024
- Published by Elsevier in Environment International
- Vol. 190, 108806
Association between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies
- 12 June 2024
- Published by Elsevier in Environment International
- Vol. 190, 108806
Open AccessAssociation between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies
- Open Access
- 6 February 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (4) , 1772-1786
High-throughput discovery of highly selective reversible hMAO-B inhibitors based on at-line nanofractionation
- 6 February 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (4) , 1772-1786
Open AccessHigh-throughput discovery of highly selective reversible hMAO-B inhibitors based on at-line nanofractionation
- Open Access
- 24 March 2023
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 17, 1164901
Exploring the research landscape of COVID-19-induced olfactory dysfunction: A bibliometric study
Since the outbreak of COVID-19, olfactory dysfunction (OD) has become an important and persistent legacy problem that seriously affects the quality of life. The purpose of this paper is to quantitatively analyze and visualize the current research status and development trend of COVID-19 related OD by using VOSviewer software. Based on the Web of Science database, a total of 1,592 relevant documents were retrieved in January 2023, with publication time spanning from 2020 to 2023. The bibliometric analysis revealed that the most influential research results in the field of COVID-19 related OD were concentrated in journals of related disciplines such as otorhinolaryngology, medicine, general and internal, virology, neurosciences, etc. The knowledge base of the research is mainly formed in two fields: COVID-19 clinical research and OD specialized research. The research hotspots are mainly concentrated in six directions: COVID-19, long COVID, smell, anosmia, OD, and recovery. Based on the results of the bibliometric analysis, the temporal trends of COVID-19 related OD studies were visually revealed, and relevant suggestions for future research were proposed.
- 24 March 2023
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 17, 1164901
Open AccessExploring the research landscape of COVID-19-induced olfactory dysfunction: A bibliometric study
Since the outbreak of COVID-19, olfactory dysfunction (OD) has become an important and persistent legacy problem that seriously affects the quality of life. The purpose of this paper is to quantitatively analyze and visualize the current research status and development trend of COVID-19 related OD by using VOSviewer software. Based on the Web of Science database, a total of 1,592 relevant documents were retrieved in January 2023, with publication time spanning from 2020 to 2023. The bibliometric analysis revealed that the most influential research results in the field of COVID-19 related OD were concentrated in journals of related disciplines such as otorhinolaryngology, medicine, general and internal, virology, neurosciences, etc. The knowledge base of the research is mainly formed in two fields: COVID-19 clinical research and OD specialized research. The research hotspots are mainly concentrated in six directions: COVID-19, long COVID, smell, anosmia, OD, and recovery. Based on the results of the bibliometric analysis, the temporal trends of COVID-19 related OD studies were visually revealed, and relevant suggestions for future research were proposed.
- Open Access
- 17 January 2023
- Published by Wiley
Cerebellar Hemorrhage Secondary to CLIPPERS: a Case Report
Cerebral hemorrhage is an extremely rare complication of CLIPPERS. We report a patient who developed CLIPPERS in his 50s and was responding to glucocorticoid therapy developed cerebellar space-occupying hemorrhage with high glucose metabolism in bilateral cerebellar hemispheres during hospitalization.
- 17 January 2023
- Published by Wiley
Open AccessCerebellar Hemorrhage Secondary to CLIPPERS: a Case Report
Cerebral hemorrhage is an extremely rare complication of CLIPPERS. We report a patient who developed CLIPPERS in his 50s and was responding to glucocorticoid therapy developed cerebellar space-occupying hemorrhage with high glucose metabolism in bilateral cerebellar hemispheres during hospitalization.
- Open Access
- 26 August 2022
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 7 (3) , e10395
Targeted brain delivery of RVG29‐modified rifampicin‐loaded nanoparticles for Alzheimer's disease treatment and diagnosis
Alzheimer's disease (AD) is an aging‐related neurodegenerative disease. The main pathological features of AD are β‐amyloid protein (Aβ) deposition and tau protein hyperphosphorylation. Currently, there are no effective drugs for the etiological treatment of AD. Rifampicin (RIF) is a semi‐synthetic broad‐spectrum antibiotic with anti‐β‐amyloid deposition, anti‐inflammatory, anti‐apoptosis, and neuroprotective effects, but its application in AD treatment has been limited for its strong hydrophobicity, high toxicity, short half‐life, low bioavailability, and blood–brain barrier hindrance. We designed a novel brain‐targeted and MRI‐characteristic nanomedicine via loading rabies virus protein 29 (RVG29), rifampicin, and Gd on poly (l‐lactide) nanoparticles (RIF@PLA‐PEG‐Gd/Mal‐RVG29). The cytotoxicity assay demonstrated that RIF@PLA‐PEG‐Gd/Mal‐RVG29 had favorable biocompatibility and security. Fluorescence imaging in vivo showed that PLA‐PEG‐Gd/Mal‐RVG29 could deliver rifampicin into the brain by enhancing cellular uptake and brain targeting performance, leading to improvement of the bioavailability of rifampicin. In in vivo study, RIF@PLA‐PEG‐Gd/Mal‐RVG29 improved the spatial learning and memory capability of APP/PS1 mice in the Morris water maze, as compared to rifampicin. Immunofluorescence, TEM, immunoblotting, and H&E staining revealed that RIF@PLA‐PEG‐Gd/Mal‐RVG29 reduced Aβ deposition in hippocampal and cortex of APP/PS1 mice, improved the damage of synaptic ultrastructure, increased the expression level of PSD95 and SYP, as well as reduced the necrosis of neurons. These findings suggest that RIF@PLA‐PEG‐Gd/Mal‐RVG29 may be an effective strategy for the treatment of AD.
- 26 August 2022
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 7 (3) , e10395
Open AccessTargeted brain delivery of RVG29‐modified rifampicin‐loaded nanoparticles for Alzheimer's disease treatment and diagnosis
Alzheimer's disease (AD) is an aging‐related neurodegenerative disease. The main pathological features of AD are β‐amyloid protein (Aβ) deposition and tau protein hyperphosphorylation. Currently, there are no effective drugs for the etiological treatment of AD. Rifampicin (RIF) is a semi‐synthetic broad‐spectrum antibiotic with anti‐β‐amyloid deposition, anti‐inflammatory, anti‐apoptosis, and neuroprotective effects, but its application in AD treatment has been limited for its strong hydrophobicity, high toxicity, short half‐life, low bioavailability, and blood–brain barrier hindrance. We designed a novel brain‐targeted and MRI‐characteristic nanomedicine via loading rabies virus protein 29 (RVG29), rifampicin, and Gd on poly (l‐lactide) nanoparticles (RIF@PLA‐PEG‐Gd/Mal‐RVG29). The cytotoxicity assay demonstrated that RIF@PLA‐PEG‐Gd/Mal‐RVG29 had favorable biocompatibility and security. Fluorescence imaging in vivo showed that PLA‐PEG‐Gd/Mal‐RVG29 could deliver rifampicin into the brain by enhancing cellular uptake and brain targeting performance, leading to improvement of the bioavailability of rifampicin. In in vivo study, RIF@PLA‐PEG‐Gd/Mal‐RVG29 improved the spatial learning and memory capability of APP/PS1 mice in the Morris water maze, as compared to rifampicin. Immunofluorescence, TEM, immunoblotting, and H&E staining revealed that RIF@PLA‐PEG‐Gd/Mal‐RVG29 reduced Aβ deposition in hippocampal and cortex of APP/PS1 mice, improved the damage of synaptic ultrastructure, increased the expression level of PSD95 and SYP, as well as reduced the necrosis of neurons. These findings suggest that RIF@PLA‐PEG‐Gd/Mal‐RVG29 may be an effective strategy for the treatment of AD.
- Open Access
- 23 March 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (3)
Warfarin-related epidural hematoma: a case report
Spinal epidural hematomas are rare, with trauma being the most common cause. Spinal epidural hematomas caused by coagulation dysfunction are even rarer; however, long-term warfarin therapy increases the risk. The clinical manifestations of spinal epidural hematoma are neurological deficits below the corresponding spinal cord segment level. Magnetic resonance imaging (MRI) is the preferred method for diagnosis, and the main treatment for epidural hematoma with typical symptoms is urgent decompression of the lumbar spine. We describe an almost 80-year-old female patient who received long-term oral warfarin therapy for atrial fibrillation. She developed sudden onset waist pain, and 2 days later, she developed pain and weakness in both lower limbs. Computed tomography (CT) of the thoracolumbar spine showed no obvious hematoma. Eight days after admission, contrast-enhanced CT of the thoracolumbar spine showed intraspinal hematomas at T5–T8 and T12–L2 levels. We performed T3–T7 laminectomy, T5–T8 hematoma removal, and spinal dural repair. The clinical symptoms did not improve significantly, postoperatively. The low incidence of spinal epidural hematoma after anticoagulation treatment means this condition is not recognized timely, and it is misdiagnosed easily. Clinicians should consider this condition when patients treated with anticoagulants have neurological deficits below a spinal segmental plane.
- 23 March 2022
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 50 (3)
Open AccessWarfarin-related epidural hematoma: a case report
Spinal epidural hematomas are rare, with trauma being the most common cause. Spinal epidural hematomas caused by coagulation dysfunction are even rarer; however, long-term warfarin therapy increases the risk. The clinical manifestations of spinal epidural hematoma are neurological deficits below the corresponding spinal cord segment level. Magnetic resonance imaging (MRI) is the preferred method for diagnosis, and the main treatment for epidural hematoma with typical symptoms is urgent decompression of the lumbar spine. We describe an almost 80-year-old female patient who received long-term oral warfarin therapy for atrial fibrillation. She developed sudden onset waist pain, and 2 days later, she developed pain and weakness in both lower limbs. Computed tomography (CT) of the thoracolumbar spine showed no obvious hematoma. Eight days after admission, contrast-enhanced CT of the thoracolumbar spine showed intraspinal hematomas at T5–T8 and T12–L2 levels. We performed T3–T7 laminectomy, T5–T8 hematoma removal, and spinal dural repair. The clinical symptoms did not improve significantly, postoperatively. The low incidence of spinal epidural hematoma after anticoagulation treatment means this condition is not recognized timely, and it is misdiagnosed easily. Clinicians should consider this condition when patients treated with anticoagulants have neurological deficits below a spinal segmental plane.
- Open Access
- 9 April 2021
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (6) , 1-8
Dl‑butylphthalide inhibits rotenone‑induced oxidative stress in microglia via regulation of the Keap1/Nrf2/HO‑1 signaling pathway
Activated microglia are a source of superoxide which often increases oxidative stress in the brain microenvironment, increase production of reactive oxygen species (ROS) and directly or indirectly lead to dopaminergic neuronal death in the substantia nigra. Thus superoxide contributes to the pathogenesis of Parkinson's disease (PD). Evidence suggests that mitochondria are the main source of ROS, which cause oxidative stress in cells. Levels of ROS are thus associated with the function of the mitochondrial complex. Therefore, protecting the mitochondrial function of microglia is important for the treatment of PD. Dl‑butylphthalide (NBP), a compound isolated from Chinese celery seeds, has been approved by the China Food and Drug Administration for the treatment of acute ischemic stroke. Recently, NBP demonstrated therapeutic potential for PD. However, the mechanism underlying its neuroprotective effect remains unclear. The present study aimed to investigate the effect of NBP on rotenone‑induced oxidative stress in microglia and its underlying mechanisms. The results demonstrated that NBP treatment significantly increased mitochondrial membrane potential and decreased ROS level in rotenone‑induced microglia. Western blot analysis showed that NBP treatment promoted entry of nuclear respiratory factor‑2 (Nrf2) into the nucleus, increased heme oxygenase‑1 (HO‑1) expression and decreased the level of the Nrf2 inhibitory protein, Kelch‑like ECH‑associated protein 1. Overall, the findings indicated that NBP inhibited rotenone‑induced microglial oxidative stress via the Keap1/Nrf2/HO‑1 pathway, suggesting that NBP may serve as a novel agent for the treatment of PD.
- 9 April 2021
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (6) , 1-8
Open AccessDl‑butylphthalide inhibits rotenone‑induced oxidative stress in microglia via regulation of the Keap1/Nrf2/HO‑1 signaling pathway
Activated microglia are a source of superoxide which often increases oxidative stress in the brain microenvironment, increase production of reactive oxygen species (ROS) and directly or indirectly lead to dopaminergic neuronal death in the substantia nigra. Thus superoxide contributes to the pathogenesis of Parkinson's disease (PD). Evidence suggests that mitochondria are the main source of ROS, which cause oxidative stress in cells. Levels of ROS are thus associated with the function of the mitochondrial complex. Therefore, protecting the mitochondrial function of microglia is important for the treatment of PD. Dl‑butylphthalide (NBP), a compound isolated from Chinese celery seeds, has been approved by the China Food and Drug Administration for the treatment of acute ischemic stroke. Recently, NBP demonstrated therapeutic potential for PD. However, the mechanism underlying its neuroprotective effect remains unclear. The present study aimed to investigate the effect of NBP on rotenone‑induced oxidative stress in microglia and its underlying mechanisms. The results demonstrated that NBP treatment significantly increased mitochondrial membrane potential and decreased ROS level in rotenone‑induced microglia. Western blot analysis showed that NBP treatment promoted entry of nuclear respiratory factor‑2 (Nrf2) into the nucleus, increased heme oxygenase‑1 (HO‑1) expression and decreased the level of the Nrf2 inhibitory protein, Kelch‑like ECH‑associated protein 1. Overall, the findings indicated that NBP inhibited rotenone‑induced microglial oxidative stress via the Keap1/Nrf2/HO‑1 pathway, suggesting that NBP may serve as a novel agent for the treatment of PD.